Hematopoiesis-modulating action of meloxicam, a cyclooxyge-nase-2 inhibitor, has been evaluated in mice. Increased serum level of granulocyte colony-stimulating factor (G-CSF) after meloxicam administration has been found in sublethally gamma-irradiated animals. In further experiments hematopoiesis-stimulating effects of meloxicam and G-CSF given alone or in combination have been investigated. Granulocyte/macrophage progenitor cells counts were used to monitor these effects. Meloxicam and exogenous G-CSF did not act synergistically when given in combination, but could be mutually substituted during their repeated administration. The results suggest a promising possibility of using meloxicam as an auxiliary drug reducing the high costs of G-CSF therapy of myelosuppression.

Laboratory of Experimental Hematology Institute of Biophysics Academy of Sciences of the Czech Republic Brno Czech Republic

Citace poskytuje Crossref.org

Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome

Hematological profile of untreated or ionizing radiation-exposed cyclooxygenase-2-deficient mice

Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review

Granulocyte colony-stimulating factor in the treatment of acute radiation syndrome: a concise review

Agonist of the adenosine A3 receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of γ-irradiated mice

Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: a review